Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Johnson and Johnson
Baxter
Merck
Mallinckrodt

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,192,662

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,192,662
Title:Methods using immunomodulatory compounds for modulating level of CD59
Abstract: Provided herein are methods of treating, preventing or managing disorders associated with low CD59 levels. The methods encompass the administration of an immunomodulatory compound provided herein, such as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline. Further described are methods of treatment using the immunomodulatory compounds in combination with other therapeutic agents or therapies. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.
Inventor(s): Brady; Helen A. (San Diego, CA), Chan; Kyle (San Diego, CA)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:12/362,411
Patent Claims:1. A method of treating or managing a disease associated with CD59 deficiency comprising administering to a patient a therapeutically effective amount of an immunomodulatory compound, wherein the immunomodulatory compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, and wherein the disease or disorder is paroxysmal nocturnal hemoglobinuria.

2. The method of claim 1, further comprising administration of an anti-C5 antibody, wherein the anti-C5 antibody is eculizumab, h5G1.1-mAb, h5G1.1-scFv, or a functional fragment of h5G 1.1.

3. The method of claim 2, wherein the anti-C5 antibody is eculizumab.

Details for Patent 9,192,662

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Celgene Corporation (Summit, NJ) 2028-01-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Merck
Medtronic
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.